Trevi Therapeutics, Inc.
TRVI
$6.47
$0.121.89%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -47.91M | -44.32M | -38.77M | -33.57M | -29.07M |
| Total Depreciation and Amortization | 147.00K | 144.00K | 143.00K | 139.00K | 123.00K |
| Total Amortization of Deferred Charges | -- | 390.00K | 390.00K | 489.00K | 570.00K |
| Total Other Non-Cash Items | 2.68M | 2.16M | 1.84M | 1.05M | 509.00K |
| Change in Net Operating Assets | 6.83M | 6.55M | 3.61M | -2.10M | -3.85M |
| Cash from Operations | -38.26M | -35.07M | -32.79M | -33.98M | -31.71M |
| Capital Expenditure | -35.00K | -50.00K | -68.00K | -80.00K | -137.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -21.49M | 15.24M | 25.57M | 42.46M | 59.57M |
| Cash from Investing | -21.53M | 15.19M | 25.50M | 42.38M | 59.43M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -126.00K | -127.00K | -126.00K | -7.79M | -9.50M |
| Issuance of Common Stock | 61.61M | 10.15M | 6.85M | 1.79M | 1.85M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -58.00K | -230.00K | -243.00K | -258.00K |
| Cash from Financing | 61.48M | 9.96M | 6.50M | -6.24M | -7.91M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.70M | -9.91M | -789.00K | 2.16M | 19.81M |